Translumina startet die globale randomisierte kontrollierte Studie „SPARX", um die Evidenzbasis für medikamentenbeschichtete Ballons bei komplexen Koronarerkrankungen zu erweitern

Impact · against what's priced in

Translumina has launched the SPARX global trial for its Protégé™ paclitaxel-coated balloon, aiming to challenge drug-eluting stents in complex coronary artery disease. While the large sample size (1,380 patients) increases the potential for guideline changes, the one-year primary endpoint means material data will not emerge until late 2027 or 2028.

Scored by the NIS engine · methodology.

• healthcare
• pharmaceuticals
• cardiology